Natural Capsules Reports Mixed Q4 FY26 Results

Standalone Profit: ₹5.52 crore | Consolidated Loss: ₹4.98 crore

Key Takeaways

Natural Capsules announced its financial results for the fourth quarter ending March 31, 2026. The company achieved a standalone profit but recorded a consolidated loss, largely impacted by its API business. A temporary manufacturing halt and leadership adjustments were also noted.

Q4 FY26 Financials

Natural Capsules Limited reported a standalone profit after tax (PAT) of ₹5.52 crore for the fourth quarter of FY26. However, its consolidated financial results for the same period showed a net loss of ₹4.98 crore.

Performance Drivers

The significant difference between standalone and consolidated figures stems from pressure within its subsidiaries. The API segment, in particular, posted a quarterly loss of ₹9.35 crore, which weighed down the overall consolidated performance, even as the standalone capsules business remained profitable.

Revenue and Segment Performance

For the quarter, Natural Capsules' standalone revenue from operations reached ₹50.80 crore, while consolidated revenue from operations stood at ₹58.45 crore. The company's core capsules segment contributed ₹8.92 crore to its profits.

Operational Updates and Changes

Investors are focused on the API segment's ongoing performance, which is a key factor affecting consolidated profitability. Operations experienced a temporary shutdown from December 2025 to January 2026 due to a regulatory matter, with production resuming on January 30, 2026. The company has also appointed new internal auditors, M/s. Mallya & Mallya, for the fiscal year 2026-27.

Key Risks

The main risks include the continued underperformance of the API segment and potential operational impacts from regulatory issues. The company has made leadership appointments, including Mr. Akshay Dutta as Company Secretary & Compliance Officer and the re-appointment of Mr. Laxminarayana Moondra as Whole-Time Director.

Other Developments

• The API segment reported losses of ₹9.35 crore in Q4 FY26 and ₹31.33 crore for the full FY26.
• The manufacturing shutdown occurred between December 26, 2025, and January 30, 2026.
• 25,000 equity shares were allotted under the ESOP 2025 scheme, increasing paid-up capital to ₹10.41 crore.
• P. Chandrasekar LLP provided an unmodified audit opinion.

What to Watch Next

Moving forward, attention will be on the strategies to turn around the API segment and any updates regarding regulatory compliance. The company's success in improving its consolidated financial performance will be critical.